Market News How it works Learn FAQ
| RCT 0.1222 60.58% | NU 12.375 -18.37% | EWZ 33.44 -21.48% | TGL 0.2449 10.56% | BBD 2.87 -29.48% | SRTM 0.3384 -21.36% | ITUB 7.555 -21.87% | AZTR 1.72 140.56% | XP 15.775 -48.13% | NVD 4.02 -4.06% | SHFS 0.0979 -26.06% | SPCX 148.81 0.89% | CLRO 4.75 46.15% | SOXL 90.94 8.83% | GCDT 0.1442 -18.11% | PBR 22 -15.90% | NWGL 0.0822 0.24% | VALE 11.895 -4.07% | TSLL 10.9402 12.09% | INTC 90.94 4.58% | SGRY 23.095 46.63% | CRWV 56.79 4.71% | NVDA 215.6 2.20% | BITO 10.6301 -1.85% | GPUS 0.1862 10.24% | SOXS 47.855 -8.78% | RBNE 0.17 -10.53% | NOK 8.6738 6.56% | ABEV 2.78 -15.76% | RWM 14.455 -0.65% | IREN 26.12 4.88% | JBLU 2.2648 -13.72% | INTR 4.525 -37.07% | TSLG 5.4701 12.32% | SBS 4.615 -27.89% | TQQQ 68.649 3.56% | XTND 2.1 18.64% | SPRC 1.5 37.61% | SPDN 8.4901 -0.58% | TSLA 395.035 6.13% | AAL 12.1593 0.41% | LUCD 0.5437 32.29% | SID 0.9326 -20.97% | SQQQ 38.275 -3.54% | PBR-A 19.3171 -17.90% | CIFR 7.9 -0.50% | GGB 4.725 -7.35% | T 21.035 0.50% | QID 14.195 -2.44% | NFLX 63.265 -3.93%
OBObsEva S.A. logo

ObsEva S.A. (OBSV)

NASDAQ Global Select · Currency in USD
$0.10 ▲ +0.00 (+0.00%)
As of Mar 22, 4:00 PM ET. Market open.

Summary

Previous Close
$0.10
Open
$0.12
Day's Range
$0.10 – $0.12
52 Week Range
$0.07 – $2.14
Volume
8,230,885
Avg. Volume
7,950,761
Market Cap
$11.00M
Beta (5Y Monthly)
0.67
PE Ratio (TTM)
--
EPS (TTM)
-$0.32
Earnings Date
--
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$6.00

Profile: ObsEva S.A.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
48
CEO
William Michael Brown
Website
obseva.com

ObsEva S.A. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative treatments for conditions affecting women's reproductive health and pregnancy. A key part of their development pipeline is Linzagolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, currently in Phase III clinical trials. This drug aims to mitigate pain associated with endometriosis and reduce heavy menstrual bleeding stemming from uterine fibroids in pre-menopausal women.

Earnings

DateEst.Actual
Mar 6, 2023-$0.06-$0.26Miss
Dec 1, 2022-$0.08-$0.13Miss
Aug 17, 2022-$0.17-$0.39Miss
May 17, 2022-$0.20-$0.14Beat
Mar 10, 2022-$0.22-$0.26Miss
Nov 4, 2021-$0.22$0.01Beat

Analyst view

Consensus price target
$6.00 ▲ +5,793.9%
Range $6.00 – $6.00
Rating: Buy
Buy 69% · Hold 23% · Sell 8%

Get free alerts on OBSV and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.